Special Issue "Pathogenesis, Diagnosis and Therapy of Ovarian Disorders and Infertility"

A special issue of Biomedicines (ISSN 2227-9059).

Deadline for manuscript submissions: 31 October 2018

Special Issue Editor

Guest Editor
Prof. Ayman Al-Hendy

Division of Translational Research, Department of Obstetrics and Gynecology, University of Illinois/Chicago (UIC), 820 South Wood Street, 2nd Fl (M/C 808), Chicago, IL 60612, USA
Website | E-Mail
Interests: premature ovarian insufficiency; premature ovarian failure; polycystic ovary syndrome; genetics; diagnosis; ovarian function; IVF; egg donation; gene therapy; stem cell therapy; hormone replacement therapy; patient perspective

Special Issue Information

Dear Colleagues,

Diseases of the ovary which most frequently cause infertility are: chronic anovulation syndromes, within which polycystic ovary syndrome plays a major role, and premature ovarian insufficiency (POI). In this special issue, we will provide the readers with an update of this broad cluster of disorders that negatively affect women’s ability to accomplish a pregnancy with an intentional focus on POI. Premature ovarian insufficiency (POI), also known as premature ovarian failure (POF), is defined as hypergonadotropic ovarian failure occurring prior to 40 years of age. It is surprisingly common and affects approximately 1% of women below 40 years of age. The incidence is 10% to 28% in women with primary amenorrhea and 4% to 18% in women with secondary amenorrhea. Affected women often face this devastating disease suddenly and start to endure a diagnosis of irreversible infertility at a young age. Many learn to live with great uncertainty about their ability to create a family—a core identity issue for many women from various cultural, religious and ethnic backgrounds. The majority of patients with POI/POF are considered to have idiopathic premature ovarian failure because usually no cause can be identified. Recent advances in understanding the etiology of POI/POF are encouraging. Clearly, the more we learn about the molecular events of early ovarian folliculogenesis, follicular atresia, ovarian stem cell biology and egg maturation, the more we can envision innovative therapeutics for POI/POF patients. Along these lines, early attempts at gene and stem cell therapy for POI/POF in preclinical models and in patients also show some promise.  In this Special Issue, we want to present the most current and cutting edge information on the etiology, pathogenesis and therapy of POI/POF. We anticipate that this Special Issue will therefore be an excellent contribution to the field and will constitute an up-to-date modern practical reference for OB/GYNs, reproductive medicine specialists, primary care practitioners and any clinician, nurse or health care worker caring for women living with POI/POF.

Prof. Ayman Al-Hendy
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access quarterly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 550 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.


  • Premature ovarian insufficiency
  • Premature ovarian failure
  • Polycystic ovary syndrome
  • Chronic anovulation
  • Genetics, diagnosis
  • Ovarian function
  • IVF
  • Egg donation
  • Gene therapy
  • Stem cell therapy
  • Hormone replacement therapy
  • Patient perspective

Published Papers (1 paper)

View options order results:
result details:
Displaying articles 1-1
Export citation of selected articles as:


Open AccessArticle Intravenous Infusion of Nucleated Peripheral Blood Cells Restores Fertility in Mice with Chemotherapy-Induced Premature Ovarian Failure
Biomedicines 2018, 6(3), 93; https://doi.org/10.3390/biomedicines6030093
Received: 4 August 2018 / Revised: 29 August 2018 / Accepted: 11 September 2018 / Published: 15 September 2018
PDF Full-text (2287 KB) | HTML Full-text | XML Full-text | Supplementary Files
Cancer treatment with specific chemotherapeutic agents has been well documented to have an adverse impact on female fertility leading to premature ovarian failure (POF). The objective of this study is to investigate if chemotherapeutic induced POF can be reversed by the infusion of
[...] Read more.
Cancer treatment with specific chemotherapeutic agents has been well documented to have an adverse impact on female fertility leading to premature ovarian failure (POF). The objective of this study is to investigate if chemotherapeutic induced POF can be reversed by the infusion of autologous nucleated peripheral blood cells (PBMC). To reach our goal, mice were treated with a single intraperitoneal injections of busulfan and cyclophosphamide to induce POF. This was followed by transfusion of PBMC. The ovarian morphology and functional parameters were monitored by radioimmunoassay, real-time PCR, immunofluorescence and immunohistochemistry analysis. Our study showed that chemotherapy (CTX) protracted estrous cycle period and repressed E2 production. In addition, CTX decreased the expressions of steroidogenesis markers, CYP-17 synthesis, StAR (steroidogenic acute regulatory protein), and Connexin-43 protein expression in the ovarian follicles. We also observed reduced numbers and sizes of the primordial and primary follicles in CTX-treated mice compared to untreated controls (p < 0.05). When both CTX and untreated control groups were stimulated with gonadotrophin, the control group produced ten times more ova than the CTX group. Finally, the treatment of premature ovarian failure induced by CTX with autologous PBMC transfusion resulted in over-expression and a statistically significant increase in several stem cell markers and restoration of fertility. Infusion with PBMC in CTX further decreased the estrous cycle length by 2.5 times (p < 0.01). We found that transfusion of autologous PBMC to mice with chemotherapy induced POF was very effective at restoring fertility. These results are similar to other studies using bone marrow derived mesenchymal stem cells. Full article

Graphical abstract

Planned Papers

The below list represents only planned manuscripts. Some of these manuscripts have not been received by the Editorial Office yet. Papers submitted to MDPI journals are subject to peer-review.

Title: Premature Ovarian insufficiency cell therapy with autologous mesenchymal  stem cells: two cases report and review
Authors: Abdeljabar El Andaloussi, Ujalla Sheikh, Hajera Takkala, Prosper Igboeli, Ayman Al-Hendy

Title: Up-date on Gene therapy of premature ovarian
Authors: Ihor Atabiekov, Elie Hobieka, Abdeljabar El Andaloussi, Ayman Al-Hendy

Type: Article
Title: Cord blood mesenchymal stem cells restore fertility in a chemotherapy-induced ovarian failure mouse model.
Authors: Sara Mohamed and etc.

Title: Mesenchymal stem cells secretome enhances proliferation and steroidogenesis in granulosa cells.
Authors: Elie Hobieka, Carlos Stocco, Ayman Al-Hendy, Abdeljabar El Andaloussi
Back to Top